Levofloxacin hepatotoxicity. Higher risk in diabetics?.

Authors

  • Joana Coelho Serviço de Medicina Interna, Hospitais da Universidade de Coimbra, Coimbra, Portugal.
  • Carla Gonçalves
  • Sara Leitão
  • R Marques Dos Santos
  • J Nascimento Costa

DOI:

https://doi.org/10.20344/amp.1529

Abstract

Levofloxacin, commonly used in medical practice, is prescribed to treat pneumonia in patients with comorbidities. Although generally well tolerated and safe, it has a well-known, but rarely reported, undercharacterized and ill-identified hepatotoxicity, with an unknown signature. With cases of fulminant hepatitis, cholestasis episodes reveal an apparently benign progression. Its capability of interference with the glucidic metabolism is also well-known, and the susceptibility factors to these events include age, presence of multiple pathologies and polymedication. The link between Diabetes Mellitus and hepatotoxicity has not yet been identified. Nonetheless, reports of several cases in literature along with the identification of two cases in insulin-treated diabetics, lead to believe that this is a higher-risk group.

Downloads

Download data is not yet available.

How to Cite

1.
Coelho J, Gonçalves C, Leitão S, Marques Dos Santos R, Nascimento Costa J. Levofloxacin hepatotoxicity. Higher risk in diabetics?. Acta Med Port [Internet]. 2011 Dec. 30 [cited 2024 Mar. 29];24:729-34. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/1529

Issue

Section

Arquivo Histórico